...
首页> 外文期刊>International Seminars in Surgical Oncology >Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients
【24h】

Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients

机译:术前双分割加速放射治疗联合治疗一系列未选择的患者的局部晚期直肠癌

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background although preoperative RT (Radiation Therapy) is becoming the preferred approach for combined treatment of locally advanced rectal adenocarcinoma, no regimen can be now considered as a standard. Since the toxicity of preoperative RT isn't yet completely known, and the advantages of preoperative RT could be counterbalanced by increased postoperative morbidity and mortality, a monocentre series of preoperative bifractionated accelerated RT was retrospectively reviewed to clarify toxicity and outcomes after a prolonged follow up. Methods patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3–4/anyN, or anyT/N1–2; ECOG Performance Status 0–2. A total dose of 41.6 Gy (26 twice daily fractions of 1.6 Gy) was delivered. Surgery was carried out 17 ± 2 days after RT completion, adopting the total mesorectal excision technique. Results 24 men and 23 women were enrolled; median age was 55 years (r.: 39–77). Twenty-eight patients were stage II and 19 stage III. 9 patients suffered from a recurrent tumour. 2 patients experienced a severe grade 4 gastrointestinal toxicity (a colo-vaginal fistula and an intestinal obstruction, both successfully treated). Operative mortality was nil; postoperative early complications occurred in 13 cases; mean length of hospital stay was 15 days. After a mean follow up of 44 months (r.: 18–84) 8 patients had deceased for recurrent disease, 15 were alive with a disease progression (2 pelvic recurrences and 13 pure distant deposits) and 24 were alive, without disease. The 5-year actuarial overall survival was 74.2%, the disease-free survival 62.9% and the regional control rate 84.7%. Long-term complications included 1 case of radiation enteritis requiring surgery, 2 cases of anastomotic stricture and 3 cases of bladder incontinence. Conclusion bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable. These findings support the increasing use of preoperative RT for treatment of this malignancy in experienced centres. Ongoing multicentric trials are expected to address still unsolved issues, including the benefit of CT adjunct to preoperative RT.
机译:背景技术尽管术前放疗(放射疗法)已成为局部晚期直肠腺癌联合治疗的首选方法,但目前尚无任何方案可作为标准。由于术前放疗的毒性尚不完全清楚,且术前放疗的优点可通过增加术后发病率和死亡率来抵消,因此,回顾性分析了单中心的术前双分数加速放疗,以明确长期随访后的毒性和预后。 。方法按照以下入选标准筛选患者:经组织学证实的直肠腺癌;距肛门边缘12 cm或更小的远端肿瘤范围;临床分期T3-4 / anyN或anyT / N1-2 ECOG绩效状态0–2。总剂量为41.6 Gy(每天两次两次,每次1.6 Gy)。在RT完成后17±2天进行手术,采用全直肠系膜切除技术。结果招募了24名男性和23名女性;中位年龄为55岁(年龄:39-77岁)。 28例患者为II期和19期III期。 9名患者患有复发性肿瘤。 2例患者出现了严重的4级胃肠道毒性(阴道阴道瘘和肠梗阻,均已成功治疗)。手术死亡率为零。术后发生早期并发症13例;平均住院时间为15天。在平均随访44个月后(r .: 18–84),有8例因复发性疾病而死亡,15例因疾病进展而活着(2例盆腔复发和13例纯远处沉积物),24例没有疾病。 5年精算总生存率为74.2%,无病生存期为62.9%,区域控制率为84.7%。长期并发症包括1例需要手术的放射性肠炎,2例吻合口狭窄和3例膀胱失禁。结论在术前对患有局部晚期直肠癌的患者进行双分割加速放疗是可靠且安全的,因为其即时和晚期毒性(主要是传染性)较低,并且可以实现长期生存。这些发现支持在经验丰富的中心越来越多地使用术前放疗来治疗这种恶性肿瘤。预计正在进行的多中心试验将解决尚未解决的问题,包括CT辅助术前放疗的益处。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号